RATIONALE: The neuropeptide pituitary adenylyl cyclase-activating peptide (PACAP) and its receptors (PAC1 and VPAC2) are expressed in the ventral tegmental area and nucleus accumbens, raising the possibility that PACAP could be a potential modulator of the mesolimbic dopaminergic system. OBJECTIVE: The present study was designed to determine if PACAP plays a role in acute motor stimulatory and rewarding actions of morphine. METHODS: The effect of intracerebroventricular PACAP administration (0, 0.03, 0.3, 1.0, or 3.0 microg/3 microL) was studied on basal motor activity as well as on morphine (5 mg/kg)-stimulated motor activity. Motor stimulation and conditioned place preference (CPP) induced by morphine (5 or 10 mg/kg) were also determined in mice lacking PACAP and their wild-type controls. RESULTS: Intracerebroventricular PACAP dose-dependently suppressed basal motor activity and PACAP-deficient mice exhibited higher basal motor activity than control mice, providing evidence that the action of endogenous PACAP on basal motor activity is inhibitory. Paradoxically, low doses of PACAP which did not alter basal motor activity were found to enhance the motor stimulatory action of morphine. Furthermore, morphine-induced motor stimulation was blunted in PACAP-deficient mice. Additionally, morphine-induced CPP following a single, but not repeated, alternate-day saline/morphine (10 mg/kg) conditioning was blunted in PACAP-deficient mice compared to their wild-type littermates/controls. CONCLUSION: The present results suggest that endogenous PACAP, at low doses, positively modulates the acute motor stimulatory and rewarding actions of morphine.
RATIONALE: The neuropeptide pituitary adenylyl cyclase-activating peptide (PACAP) and its receptors (PAC1 and VPAC2) are expressed in the ventral tegmental area and nucleus accumbens, raising the possibility that PACAP could be a potential modulator of the mesolimbic dopaminergic system. OBJECTIVE: The present study was designed to determine if PACAP plays a role in acute motor stimulatory and rewarding actions of morphine. METHODS: The effect of intracerebroventricular PACAP administration (0, 0.03, 0.3, 1.0, or 3.0 microg/3 microL) was studied on basal motor activity as well as on morphine (5 mg/kg)-stimulated motor activity. Motor stimulation and conditioned place preference (CPP) induced by morphine (5 or 10 mg/kg) were also determined in mice lacking PACAP and their wild-type controls. RESULTS: Intracerebroventricular PACAP dose-dependently suppressed basal motor activity and PACAP-deficient mice exhibited higher basal motor activity than control mice, providing evidence that the action of endogenous PACAP on basal motor activity is inhibitory. Paradoxically, low doses of PACAP which did not alter basal motor activity were found to enhance the motor stimulatory action of morphine. Furthermore, morphine-induced motor stimulation was blunted in PACAP-deficient mice. Additionally, morphine-induced CPP following a single, but not repeated, alternate-day saline/morphine (10 mg/kg) conditioning was blunted in PACAP-deficient mice compared to their wild-type littermates/controls. CONCLUSION: The present results suggest that endogenous PACAP, at low doses, positively modulates the acute motor stimulatory and rewarding actions of morphine.
Authors: H Hashimoto; H Nogi; K Mori; H Ohishi; R Shigemoto; K Yamamoto; T Matsuda; N Mizuno; S Nagata; A Baba Journal: J Comp Neurol Date: 1996-08-05 Impact factor: 3.215
Authors: Anthony J Harmar; W John Sheward; Christine F Morrison; Beatrice Waser; Mathias Gugger; Jean Claude Reubi Journal: Endocrinology Date: 2003-11-14 Impact factor: 4.736
Authors: D Reglodi; P Kiss; K Szabadfi; T Atlasz; R Gabriel; G Horvath; P Szakaly; B Sandor; A Lubics; E Laszlo; J Farkas; A Matkovits; R Brubel; H Hashimoto; A Ferencz; A Vincze; Z Helyes; L Welke; A Lakatos; A Tamas Journal: J Mol Neurosci Date: 2012-04-14 Impact factor: 3.444
Authors: Marjorie R Levinstein; David J Bergkamp; Zoë K Lewis; Alex Tsobanoudis; Koichi Hashikawa; Garret D Stuber; John F Neumaier Journal: Genes Brain Behav Date: 2022-03-18 Impact factor: 3.708
Authors: Alexander T Nguyen; Paul Marquez; Abdul Hamid; Brigitte Kieffer; Theodore C Friedman; Kabirullah Lutfy Journal: Eur J Pharmacol Date: 2012-05-02 Impact factor: 4.432
Authors: Valentina Sabino; Pietro Cottone; Antonio Ferragud; Clara Velazquez-Sanchez; Margaret A Minnig Journal: Neuropsychopharmacology Date: 2020-11-16 Impact factor: 7.853